Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Preclinical studies suggest K+ channel TASK-1 to be potential target of antiepileptic drugs

Jan. 2, 2008

Phase IIa MEM-3454 trial begins for cognitive impairment in schizophrenia

Jan. 2, 2008

U.K. report cites Hemispherx's Ampligen as a potential aid for CFS

Jan. 2, 2008

Endo to develop and commercialize Alexza's AZ-003 Staccato inhaled fentanyl

Jan. 2, 2008

Targeting ASICs may provide benefit in multiple sclerosis

Jan. 2, 2008

Antisense provides update on ATL-1102 phase IIa multiple sclerosis trial

Dec. 31, 2007

Collegium reports results for its abuse deterrent sustained release opioid study

Dec. 31, 2007

CytRx initiates phase IIb trial with arimoclomol for the treatment of ALS

Dec. 31, 2007

AVI BioPharma starts dosing in Duchenne muscular dystrophy trial

Dec. 31, 2007

Lundbeck and Paion expand license agreement for desmoteplase

Dec. 31, 2007

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...